



- (51) **International Patent Classification:**
A61K 47/48 (2006.01) *C07K 14/65* (2006.01)
- (21) **International Application Number:**
PCT/IB2014/066806
- (22) **International Filing Date:**
11 December 2014 (11.12.2014)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
61/915,090 12 December 2013 (12.12.2013) US
- (71) **Applicants (for all designated States except US):** **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH). **LEK PHARMACEUTICALS D.D.** [SI/SI]; Verovškova 57, 1526 Ljubljana (SI).
- (72) **Inventors; and**
- (71) **Applicants (for US only):** **JEVSEVAR, Simona** [SI/SI]; LEK PHARMACEUTICALS D.D., Verovškova 57, 1526 Ljubljana (SI). **KUNSTELJ, Menci** [SI/SI]; LEK PHARMACEUTICALS D.D., Verovškova 57, 1526 Ljubljana (SI). **PODOBNIK, Barbara** [SI/SI]; LEK PHARMACEUTICALS D.D., Verovškova 57, 1526 Ljubljana (SI).
- (74) **Common Representative:** **NOVARTIS AG**; Lichtstrasse 35, CH-4056 Basel (CH).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:


— with international search report (Art. 21(3))

[Continued on next page]

(54) **Title:** A PROCESS FOR PREPARING A COMPOSITION OF PEGYLATED PROTEINS

Figures

Figure 1: Process flow diagram



(57) **Abstract:** This invention is in the field of protein pegylation. In particular, it relates to a method for pegylating therapeutic proteins. The invention also relates to the use of such pegylated therapeutic polypeptides for treating muscle diseases and disorders.



-
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*